By Bonnie Eslinger (June 16, 2023, 11:11 PM EDT) — A Harvard University professor emeritus testifying in a federal antitrust trial Friday over claims Gilead and Teva illegally delayed generic versions of HIV medications told a California jury that the suit’s end-payor classes were overcharged $1.5 billion — provoking Gilead to challenge that amount at cross-examination using opinions from its own Harvard expert….
- SEO Powered Content & PR Distribution. Get Amplified Today.
- EVM Finance. Unified Interface for Decentralized Finance. Access Here.
- Quantum Media Group. IR/PR Amplified. Access Here.
- PlatoAiStream. Web3 Data Intelligence. Knowledge Amplified. Access Here.
- Source: https://www.law360.com/ip/articles/1689993?utm_source=rss&utm_medium=rss&utm_campaign=section